Early HER2-positive breast cancer arising from a fibroadenoma: a case report
Author(s) -
Akihiro Fujimoto,
Kazuo Matsuura,
Tomonori Kawasaki,
Yuki Ichinose,
Asami Nukui,
Miyuki Hiratsuka,
Aya Asano,
Hiroko Shimada,
Akihiko Osaki,
Toshiaki Saeki
Publication year - 2021
Publication title -
oxford medical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.169
H-Index - 9
ISSN - 2053-8855
DOI - 10.1093/omcr/omab083
Subject(s) - medicine , breast cancer , fibroadenoma , pathological , biopsy , inflammatory breast cancer , sentinel lymph node , oncology , stage (stratigraphy) , invasive ductal carcinoma , cancer , radiology , pathology , paleontology , biology
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a case of HER2-positive breast cancer arising from FA that was treated with chemotherapy plus anti-HER2 therapy. In this early case, upfront surgery outcomes guided the selection of appropriate systemic therapy. A 31-year-old woman previously diagnosed with FA experienced tumor growth. Core needle biopsy and imaging studies confirmed a diagnosis of stage IIA HER2-positive invasive ductal carcinoma (IDC) with no evidence of lymph node metastasis (cT2N0M0). Breast-conserving surgery was performed. Pathological diagnosis revealed stage IA IDC with a predominant intraductal component (pT1aN0M0), arising from FA. In conclusion, we encountered an extremely rare case of HER2-positive breast cancer arising from FA in which pathological infiltration was difficult to predict based on preoperative imaging.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom